RAFAEL HOLDINGS, INC. Marketable Securities, Unrealized Gain (Loss)
RAFAEL HOLDINGS, INC. (RFL) reported Marketable Securities, Unrealized Gain (Loss) of $33.00 thousand for the 12-month period ending 2023-07-31, per its 10-K filed 2023-10-30.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2023-10-30
- RAFAEL HOLDINGS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2023-07-31 was -$121.00K.
- RAFAEL HOLDINGS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2023-04-30 was $0.00.
- RAFAEL HOLDINGS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2023-01-31 was $139.00K.
- RAFAEL HOLDINGS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2022-10-31 was $15.00K.
- RAFAEL HOLDINGS, INC. marketable securities, unrealized gain (loss) for fiscal 2023 was $33.00K.
- RAFAEL HOLDINGS, INC. marketable securities, unrealized gain (loss) for fiscal 2022 was -$45.00K.
- RAFAEL HOLDINGS, INC. marketable securities, unrealized gain (loss) for fiscal 2018 was -$308.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2023-07-31 | -$121.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-30 | -$121.00K derived: sum of 2 quarters · filed 2023-10-30 | $18.00K derived: sum of 3 quarters · filed 2023-10-30 | $33.00K 10-K · filed 2023-10-30 |
| 2023-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-13 | $139.00K derived: sum of 2 quarters · filed 2023-06-13 | $154.00K 10-Q · filed 2023-06-13 | $111.00K derived: sum of 4 quarters · filed 2023-06-13 |
| 2023-01-31 | $139.00K 10-Q · filed 2023-03-14 | $154.00K 10-Q · filed 2023-03-14 | $111.00K derived: sum of 3 quarters · filed 2023-03-14 | $109.00K derived: sum of 4 quarters · filed 2023-06-13 |
| 2022-10-31 | $15.00K 10-Q · filed 2022-12-13 | -$28.00K derived: sum of 2 quarters · filed 2022-12-13 | -$30.00K derived: sum of 3 quarters · filed 2023-06-13 | |
| 2022-07-31 | -$43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31 | -$45.00K derived: sum of 2 quarters · filed 2023-06-13 | -$45.00K 10-K · filed 2022-10-31 | |
| 2022-04-30 | -$2.00K 10-Q · filed 2023-06-13 | -$2.00K 10-Q · filed 2023-06-13 | ||
| 2018-07-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-10-04 | -$308.00K derived: sum of 2 quarters · filed 2019-10-04 | -$308.00K 10-K · filed 2019-10-04 | |
| 2018-04-30 | -$311.00K 10-Q · filed 2019-06-05 | -$311.00K 10-Q · filed 2019-06-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |